Incivek and Tipranavir Capsules

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using telaprevir together with tipranavir may reduce the blood levels and effects of both medications, which may make them less effective in the treatment of hepatitis C and HIV infection. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Let your doctor know if your conditions worsen during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Concomitant use of telaprevir with tipranavir/ritonavir has not been studied. Coadministration of telaprevir and some ritonavir-boosted protease inhibitor regimens has been associated with decreased plasma concentrations of both telaprevir and/or the protease inhibitors. The mechanism of interaction has not been described. In 14 study subjects, administration of telaprevir (750 mg every 8 hours for 10 days) in combination with darunavir/ritonavir (600 mg/100 mg twice daily for 20 days) reduced the telaprevir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) by an average of 36%, 35% and 32%, respectively. The Cmax, AUC and Cmin of darunavir were also reduced by approximately 40% each. In a similar study with 18 volunteers, fosamprenavir/ritonavir (700 mg/100 mg twice daily for 20 days) reduced the Cmax, AUC and Cmin of telaprevir by approximately one-third each, while telaprevir reduced the Cmax, AUC and Cmin of amprenavir by an average of 35%, 47% and 56%, respectively. Telaprevir given in a different dosing regimen (1125 mg every 12 hours for 4 days) reduced the Cmax, AUC and Cmin of amprenavir by 40%, 49% and 58%, respectively. When telaprevir (750 mg every 8 hours for 10 days) was given with atazanavir/ritonavir (300 mg/100 mg once daily for 20 days) to 14 study subjects, telaprevir Cmax, AUC and Cmin decreased by an average of 21%, 20% and 15%, respectively, while the AUC and Cmin of atazanavir increased by 17% and 85%, respectively. In 12 study subjects, lopinavir/ritonavir (400 mg/100 mg twice daily for 20 days) reduced the telaprevir Cmax, AUC and Cmin by approximately one-half, while telaprevir had no significant effect on lopinavir pharmacokinetics.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, coadministration of telaprevir and tipranavir/ritonavir is not recommended based on available data.

Incivek

Generic Name: telaprevir

Brand name: Incivek

Synonyms: n.a.

What is Incivek?

Tipranavir Capsules

Generic Name: tipranavir

Brand name: Aptivus

Synonyms: Tipranavir

What is Tipranavir Capsules?